Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21917400 | 0.75 | KDM4E (0.44) | LMNAALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL21844002 | 0.75 | NPC1 (0.43) | MEN1KMT2AALDH1A1HSD17B10HPGD | |
| SCHEMBL21917401 | 0.74 | TRPV1 (0.44) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL24946251 | 0.74 | SORD (0.42) | — | |
| SCHEMBL3205032 | 0.73 | CYP3A4 (0.53) | LMNACYP3A4CYP2D6TSHRMEN1 | |
| SCHEMBL30079990 | 0.72 | CYP3A4 (0.56) | LMNACYP3A4CYP2D6TSHRMEN1 | |
| SCHEMBL2168776 | 0.69 | KDM4E (0.60) | LMNACYP3A4CYP2D6TSHRMEN1 | |
| SCHEMBL3339822 | 0.69 | KDM4E (0.60) | LMNACYP3A4CYP2D6TSHRMEN1 | |
| SCHEMBL18228600 | 0.69 | KDM4E (0.60) | LMNACYP3A4CYP2D6TSHRMEN1 | |
| SCHEMBL10498542 | 0.69 | LMNA (0.70) | LMNACYP3A4CYP2D6TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590076-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | LMNA 2483/4885CYP3A4 2465/4885CYP2D6 4268/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | LMNA 2483/4885CYP3A4 2465/4885CYP2D6 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.